Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2014

View Archived Issues

FISSEQ technique developed for spatial resolution of gene expression

BC-001 shows efficacy in breast and renal cell carcinoma xenograft models

Bayer Schering Pharma identifies novel benzazepine bromodomain-containing protein 4 inhibitor

New biomarker identified for neuroblastoma

Gilead presents promising results from phase III ION-1, ION-2 and ION-3 trials

Pfizer discloses new EZH2 inhibitors for cancer

Nitto Denko to advance anti-fibrosis siRNA into phase I/II

Antibody-drug conjugates including DGN-462 demonstrate anticancer activity

NICE provides guidance on two treatments for lung cancer

Chinese researchers disclose new agents for HCV infection

Biodel and HEC Pharm subsidiary to develop ultra-rapid-acting insulin aspart

Novel translocator protein PET ligand synthesized for imaging glioma

Custirsen plus cabazitaxel/prednisone obtains FDA fast track designation

FDA approves siltuximab for multicentric Castleman's disease

Researchers at Bayer Schering Pharma present new agents for hyperproliferative disorders

Valeant proposes merger with Allergan

FDA clears study of ProHema in pediatric patients

Novel DPP IV inhibitors disclosed by Qilu Pharmaceutical

Avalanche Biotechnologies secures funding to advance retinal disorder pipeline

Courtagen to genetically profile patients at Connecticut Children's Autism Neurogenetics Clinic

Synthetic Biologics reports preclinical data for novel pertussis therapeutic

Lupin and Yoshindo to create joint venture

AveXis closes financing round to advance its SMA gene therapy program

Roche recaps progress of first quarter 2014

FDA awards orphan drug designation to Tolero's alvocidib for AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...